Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Labcyte and FIMM Announce a Collaboration Enabling “Real-Time” Science to Advance Personalized Medicine in Cancer Treatments

Published: Tuesday, January 08, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Collaboration expected to further the development of personalized medicine in cancer treatment.

Labcyte Inc. and the Institute for Molecular Medicine Finland (FIMM) are collaborating to further the development of personalized medicine in cancer treatment. Labcyte acoustic liquid handling technology has already revolutionized small-molecule research. Now, FIMM, a European leader in advanced research for new cancer therapies, will apply the technology extensively in its personalized medicine programs.

“FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.”
“FIMM’s groundbreaking use of acoustic liquid handling will demonstrate the technology’s role in genetic research,” said Mark Fischer-Colbrie, CEO of Labcyte. “FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.”

FIMM uses large sample sets with links to detailed patient records and genetic data to discover personalized treatment options at a faster pace.

“We see an enormous potential in expanding our use of Labcyte acoustic dispensing technology to help discover specialized leukemia treatments,” said Professor Olli Kallioniemi, director of FIMM. “This research is based on high-throughput drug sensitivity and resistance testing of leukemic cells taken from patients. This new initiative will bring us closer to the clinic and closer to patients.”

“Our aim is to find alternate treatment options for patients who simultaneously undergo treatment in the clinic,” said Kallioniemi. “We will be doing real-time science, using new scientific insights and technologies to help patients who have failed standard leukemia treatments.”

Increasing its throughput enables FIMM to do more rapid and more efficient testing. Researchers at the Institute hope to learn how leukemia cells ex-vivo respond to various types of drugs, and what the resistance mechanisms are. “Larger trials with samples from acute myeloid leukemia patients who have relapsed under standard treatment may quickly suggest individualized treatment options using existing cancer drugs,” added Kallioniemi. “We’re not saying we can cure leukemia, but for patients who have run out of options, alternative treatments may be available sooner.”

By working with FIMM to utilize acoustic liquid handling in genetics research, Labcyte will continue to expand the application of its technology in bio-marker discovery, single-cell analysis, RT-qPCR, genotyping, siRNA screening, and bio-banking.

“We are excited to be an enabling platform for improving patient care with FIMM,” said Fischer-Colbrie. “It will continue to demonstrate how acoustic liquid handling enhances life science research.”

“This research may be changing the way new and emerging drugs are introduced for patients—it is truly game-changing,” said Kallioniemi. “Labcyte technology is a key enabling platform for this drug-sensitivity testing.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Labcyte Inc. Closes $5.3 Million Financing
Privately-held company with products that advance acoustic liquid handling closes a Series D financing.
Thursday, January 10, 2013
Cancer Research Technology Selects the Labcyte Access™ Laboratory Workstation
Labcyte Access workstation to automate the production of assay-ready plates used in CRT's high-throughput cell based screening program
Monday, June 25, 2012
Scientific News
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Expanding Knowledge of Viral Diversity
Environmental datasets help researchers double the number of microbial phyla known to be infected by viruses.
Computers Better Predict Lung Cancer Type, Severity
Study shows automating the analysis of cancer tissue samples increases the accuracy of tumor classification and patient prognoses.
Using Big Data to Discover Potential Cancer Biomarkers
University of Hawai'i Cancer Center researchers used "Big Data" to discover potential cancer biomarkers, a panel of six long intergenic non-coding RNAs (lincRNAs), for the diagnosis of all types of cancers including lung, breast, prostate, liver and ovarian cancers.
Protecting Privacy in Genomic Databases
System helps ensure databases used in medical research will not leak patients’ personal information.
Algorithm To Find Precise Cancer Treatments For Patients Developed
The JAMMIT algorithm could help predict which patients will benefit most from chemotherapy.
Depression Genetics Insight from Crowd-Sourced Data
Genome sites liked to depression have been discovered from data shared by people who had purchased their genetic profiles online.
Detecting Hazardous Chemicals in Complex Mixtures
Researchers are pioneering a new chemical substance analyis software technique that could increase illicit substance detection.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!